Evidence map›Paper›PMID 42034055›Full record

ArticleCell reports. Medicine2026

An inhalable microbe-oncolytic virus consortium for lung cancer treatment.

Hao Ling, Shihua Yang, Xianbao Shi, Zhenguo Cheng, Wei Wang, Meng Niu, Funan Liu, Jin Sun, Mengchi Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hao LingWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
Shihua YangDepartment of Breast Surgery, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning 110042, China.
Xianbao ShiDepartment of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, China.
Zhenguo ChengSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, China.
Wei WangPulmonary and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
Meng NiuDepartment of Interventional Therapy, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China. Electronic address: 13998217255@163.com.
Funan LiuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, China Medical University, Ministry of Education, Shenyang, Liaoning 110001, China. Electronic address: fnliu@cmu.edu.cn.
Jin SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang, Liaoning 110016, China. Electronic address: sunjin@syphu.edu.cn.
Mengchi SunJoint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang, Liaoning 110016, China; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Electronic address: sunmengchi@syphu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses (OVs) represent a promising cancer therapy due to their selective cytotoxicity, yet clinical success in lung cancer is hindered by biological barriers and immunosuppressive microenvironments. To address these barriers, an inhalable microbe-OVs consortium is developed by conjugating tumor-responsive PEGylated adenoviruses (Ads) to motile algae (Synechococcus WH8102) via click chemistry. Driven by algal motility, the consortium penetrates respiratory mucus and epithelial barriers to reach lung tumor sites. Intratumoral calcium ion deprivation by the algae disrupts cellular tight junctions and facilitates deep penetration into solid tumors, thereby potentiating Ads-mediated immunogenic cell death (ICD) and boosting microbial and viral co-activated antitumor immunity. Inhalation administration demonstrates robust antitumor effectiveness in murine lung tumor. This inhalable microbe-OV strategy provides a promising scheme for clinical oncolytic microorganism biotherapeutics.

Indexed as

Lung NeoplasmsOncolytic VirotherapyOncolytic VirusesAdenoviridaeAdministration, InhalationAnimalsCell Line, TumorHumansMiceantitumor immunityinhalablemicrobe-OVs consortiumoncolytic microorganism biotherapeuticsoncolytic viruses

Identifiers

PMID42034055
PMCPMC13198308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.